Abstract | Currently , no disease-modifying osteoarthritis drugs (DMOADs) have been approved. Past clinical trials have failed for several reasons, including the commonly applied definition of eligibility based on radiographic assessment of joint structure. In the context of precision medicine, finding the appropriate patient for a specific treatment approach will be of increasing relevance. Phenotypic stratification by use of imaging at the time of determining eligibility for clinical trials will be paramount and cannot be achieved using radiography alone. Furthermore, identification of joints at high risk of rapid progression of osteoarthritis is needed in order to enable a more efficient DMOAD trial design. In addition, joints at high risk of collapse need to be excluded at screening. The use of MRI might offer advantages over radiography in this context. Technological advances and simplified image assessment address many of the commonly perceived barriers to the application of MRI to assessment of eligibility for DMOAD clinical trials.
Although a number of potential disease-modifying pharmacological compounds have been investigated for osteoarthritis (OA) in the past two decades (including, but not limited to, inducible nitric oxide synthase (iNOS), strontium ranelate, calcitonin, matrix metalloproteinase (MMP) inhibitors, cathepsin K inhibitors and bisphosphonates) [1] [2] [3] [4] , no pharmacological agent has yet been approved by regulatory agencies as a disease-modifying osteoarthritis drug (DMOAD). Estimates published in 2016 put the cost of developing a prescription drug that gains market approval at US$2.6 billion, an increase of 145% since 2003, and the discontinuation of several late-stage drug development programmes also suggests the need to carefully reconsider the process for developing DMOADs 5 . Selection criteria for determining patient eligibility for clinical trials are important in this regard, as even the most efficacious compound and complete loss of joint space are also excluded from DMOAD trials owing to potential ceiling effects -that is, no further radiographic progression is possible 7 . However, as demonstrated by a population-based observational study that reported the presence of MRI-detected osteophytes in 74% of knees with normal radiographs (that is, KL grade 0), radiography lacks sensitivity not only for the visualization of specific bony features of OA, such as osteophytes, but also for the detection of additional features of OA, such as soft tissue changes due to insufficient contrast resolution 8 . Cartilage damage is considered to be one of the hallmarks of OA. Other pathological features of OA that are not visualized by radiography but are considered to be associated with pain include subchondral bone marrow lesions (BMLs), synovitis, joint effusion, periarticular cystic lesions and meniscal tears 9 . The aforementioned population-based observational study reported the prevalence of BMLs, meniscal tears, and synovitis or effusion as being as high as 52%, 24%, and 36%, respectively 8, 10 . These findings suggest that knees with KL grade 0 or 1 should not automatically be considered structurally normal, and patients with such knees could be considered for inclusion in OA clinical trials.
A joint contains many different tissues that can exhibit pathological changes, providing many potential targets for treatment. Consequently, a single treatment for OA is unlikely to be similarly efficacious in preventing or delaying the progression of all types of structural OA. Researchers are increasingly suggesting that OA comprises several phenotypes or subpopulations, defined on the basis of pathophysiology and structural manifestations of disease [11] [12] [13] . These phenotypes might be characterized by distinct clinical features, laboratory parameters, biochemical markers and/or imaging criteria 14 . We hypothesize that refocusing on the starting point of any DMOAD trial, namely, the eligibility criteria, could potentially improve the prospect of developing a successful treatment. Structural characterization based on imaging findings is one aspect will only work if targeted to an appropriate patient population.
Most clinical DMOAD trials have focused on the knee joint for several reasons including the prevalence of knee OA, the anatomy of the knee (articular cartilage is relatively prominent in the knee compared with other joints) and the feasibility of assessing joint space width in the knee using radiography [1] [2] [3] [4] 7 . Currently, recruitment of participants for DMOAD trials is dependent on radiographic structural disease severity as defined by the Kellgren-Lawrence (KL) scale 6 . Knees with KL grade 0 or 1 are considered not to have structural OA and are thus excluded from DMOAD trials, whereas knees with evidence of definite osteophytes (that is, KL grade 2) or joint space narrowing (KL grade 3) are considered to have radiographic OA and, thus, are potentially eligible. Commonly, knees exhibiting end-stage disease (KL grade 4) with bone-on-bone appearance on an anterior-posterior radiograph
The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA used to define inclusion criteria for clinical trials; demographic and clinical parameters, including age, pain, function, BMI, knee alignment and others, are also relevant but are beyond the scope of this article. In this Opinion article, we describe some of the problems that particularly affect eligibility criteria for knee OA trials from an imaging standpoint and provide a rationale as to why it might be time for a shift from radiography to MRI as the primary imaging modality for defining eligibility criteria, which would enable the characterization of different structural phenotypes of knee OA on the basis of MRI.
Why radiography is insufficient
In our view, the inclusion of patients in clinical trials on the basis of radiographic assessment to define a structural disease is insufficient or even misleading for several reasons. First, the radiography-based definition of OA severity is insufficient. Second, radiographically depicted structural changes are only weakly associated with pain. Third, radiography cannot adequately visualize the various structural phenotypes of OA. Finally, radiography is unable to detect some potentially detrimental findings that could indicate increased risk of joint collapse or disease that will progress rapidly regardless of treatment. In this section, we discuss each of these reasons in further detail.
Definition of disease severity. As mentioned above, so-called radiographically normal knees exhibit a spectrum of tissue pathologies on MRI and thus cannot necessarily be considered structurally normal 8, 10 ( Fig. 1) . Variations in knee positioning substantially influence the assessment of most radiographic characteristics of OA. This influence seems to be relevant for semiquantitative as well as quantitative evaluation, as exemplified in the Cohort Hip and Cohort Knee (CHECK) study, in which systematic variation in semi-flexed knee joint positioning during image acquisition influenced the measurement of several radiographic parameters, including joint space width 15 , which could lead to misclassification (false-positive or false-negative) of joint space narrowing as shown in Fig. 2 .
Pain-structure associations. Substantial discordance between radiographically diagnosed OA and knee pain has been reported in population-based studies 16, 17 . Whereas radiographic evidence of joint damage is associated with a predisposition to joint pain, the underlying pathologies that lead to knee pain cannot be readily discerned from radiography alone and might require consideration of other factors 18 ( Fig. 3) . Novel study designs are one approach to dealing with this so-called structure-symptom discordance. For example, in a study that adequately accounted for inter-individual differences that influence the pain experience (including factors such as genetics, sensitization, mood, coping, catastrophizing and social context, among others), a strong relationship between radiographic OA and knee pain was observed 19 . Despite radiography being the most widely used first-line imaging modality for structural evaluation in OA, its inherent limitations should be noted, primarily its lack of ability to directly visualize the majority of OA-related pathological features in and around the joint that are potentially responsible for symptoms related to the disease. In MRI studies, by contrast, several structural alterations, such as meniscal tears, subchondral BMLs, subarticular bone attrition, synovitis and effusion, have been associated with knee pain [20] [21] [22] . Furthermore, changes in BMLs and inflammatory markers on MRI, such as effusion-synovitis and Hoffa-synovitis, two features commonly assessed on non-enhanced MRI as surrogates for whole-knee synovitis, have been associated with fluctuations in pain in patients with knee OA 23 . How much of the variance in pain is accounted for by structural changes in the knee is not fully understood. One reason for this difficulty could be that most studies of the associations between pain and structure have focused on late-stage disease, when numerous pathological changes are already commonly present.
Structural phenotypes of osteoarthritis.
OA has different structural phenotypes that cannot be adequately characterized using radiography 13 . Owing to limitations in clinical trial duration, DMOAD efficacy might be most efficiently investigated in patients at risk of rapid progression of OA, which could be labelled a fast progressor phenotype, and researchers are working to better understand which joints are at risk of such an accelerated disease evolution 24, 25 . In addition to this fast progressor phenotype, several other structural phenotypes of OA have been proposed: an inflammatory (or synovial) phenotype; a bone phenotype, characterized by marked subchondral bone changes; a meniscal phenotype, which causes altered biomechanics and subsequent cartilage loss; and hypertrophic and atrophic phenotypes, characterized by the presence or absence, respectively, of osteophyte formation 13, 26, 27 . Of these phenotypes, only the last two can be adequately characterized using radiography. 
Missed exclusionary findings.
Several lesions that cannot be detected using radiography, including (but not limited to) findings that are visible only on MRI, can lead to marked alterations in biomechanics and/or perfusion and eventual joint collapse and might not be amenable to treatment with a potential DMOAD. These entities include subchondral insufficiency fracture, osteonecrosis, meniscal root tears, malignant bone marrow infiltration and synovial tumours, which, if not adequately treated, could lead to joint collapse as manifested by the disintegration of the articular surface and subsequent structural deterioration, including depression of the articular surface and dislocation of osteochondral fragments 28, 29 . These entities are considered rare overall, although data on their prevalence in the context of OA clinical trials are not available. Joints with these diagnoses are commonly included in epidemiological and clinical studies; for example, a free-text search of a retrospective institutional database found that 84 cases of medial or lateral femoral condyle subchondral insufficiency fracture were described over a 13-year period 30 .
Why MRI might offer solutions MRI enables OA researchers to overcome some of the limitations of radiography as it offers a tomographic viewing perspective (unlike radiography, which is a projectional 2D technique) 31 . MRI can depict all joint tissues, including tissues that could be responsible for the pain experienced in OA [20] [21] [22] [23] , and might thus enable a more expansive phenotypic characterization than radiography 32 . Finally, MRI enables screening for individuals at risk of an adverse event. To date, however, MRI has been perceived as a tool that is too complex and expensive to be applied in large-scale endeavours, such as eligibility screening for clinical DMOAD trials. As such, radiography is still the imaging method most commonly used for defining eligibility based on joint structure. We argue that this paradigm should be revised, particularly in light of technological advances relevant to MRI, as summarized in Box 1.
Advanced image acquisition.
Although MRI has been clinically applied for >30 years with a very low risk profile when contraindications (for example, cardiac pacemakers) are carefully considered, MRI of a knee joint is still relatively time consuming in comparison with radiography. This time constraint could be one reason for MRI being perceived as not feasible for large-scale screening efforts. Other limitations of MRI include associated costs, the fact that only a single joint can be imaged at one time, limits regarding obese patients (most scanners accommodate a maximum weight of 180 kg), the exclusion of patients with cardiac pacemakers or the detection of incidental findings of unknown clinical relevance. However, advances in MRI technology have markedly accelerated image acquisition such that imaging time could potentially be reduced to a fraction of previous acquisition times. Specific technical advances include parallel imaging or improvements in 3D fast spin echo imaging, which now allow for acquisition of tri-planar MRI of the knee with fluid-sensitive fat-suppressed contrast in <5 min [33] [34] [35] . These methodological advances have the potential to be applied to large-scale knee OA screening endeavours with markedly reduced image acquisition time and costs 36 .
Simplified image assessment. Another challenge of using MRI as an OA screening tool is that current assessment tools focus on the involvement of multiple tissues in OA. Semiquantitative multi-tissue approaches are labour-intensive and challenging to apply in a screening setting intended to identify individuals eligible for inclusion in a clinical trial, as several thousands of subjects might need to be screened. Current semiquantitative scoring systems assess several pathological features of OA, including BMLs, subchondral cysts, articular cartilage, osteophytes, Hoffa-synovitis and effusion-synovitis, meniscus, tendons and ligaments, and periarticular features such as cysts and bursitides [37] [38] [39] [40] [41] . The aim of any MRI-based screening in the context of eligibility for DMOAD trials would be to define subpopulations that exhibit specific OA phenotypes most likely to benefit from a given pharmacological intervention. As an example, for a trial of a compound with an anti-inflammatory mechanism of action, the goal would be to enrich the trial population with individuals exhibiting an inflammatory phenotype. Such a phenotype could be defined by use of MRI as having a high prevalence of synovitis, joint effusion or, potentially, BMLs. In addition, the inclusion of individuals who are likely to have rapid disease progression would be desirable given the limited duration of clinical trials. In order to achieve such phenotypic characterization during a b c screening for DMOAD trial eligibility, which would focus on phenotypic characterization and findings that would exclude a patient from a trial, elaborate whole-organ assessment would not be needed. Instead, a simplified instrument could be utilized, using a tri-compartmental anatomical approach to define the compartment or compartments most affected and then applying a simplified assessment focused on the mechanism of action of the DMOAD under study -including measures of BMLs, meniscus, cartilage, osteophytes and inflammation, as appropriate -to aid in defining a specific structural phenotype.
Phenotypic stratification. The identification of OA phenotypes, preferably through the use of simple technologies, to allow for patient stratification and then matching of the best intervention to each individual phenotype has been previously identified as an urgent medical need 25, 26 . From a structural, MRI-centric perspective, we posit that five different OA phenotypesnamely the aforementioned inflammatory, bone, meniscal, hypertrophic and atrophic phenotypes -can be differentiated based on the tissues that are most severely affected by the disease. Examples of the different MRI-defined structural phenotypes are shown in Figs. 1, 4 . These phenotypes exhibit distinct structural characteristics, such as the absence or presence of osteophytes in atrophic or hypertrophic phenotypes, or possess structural characteristics that predispose a joint to faster disease progression. This concept has clear limitations based on the fact that structural phenotypes probably overlap, and more than one could be present in an individual. OA is a heterogeneous disease with different pathways involving multiple tissues that exhibit structural damage. For this reason, we suggest characterizing a predominant structural phenotype. Definition of these phenotypes will certainly need to be refined, and novel analytical approaches could help in doing so 14, 42, 43 . An inflammatory phenotype would be defined by marked synovitis and/or joint effusion on MRI. Synovitis in OA is thought to be a secondary phenomenon related to cartilage deterioration, and synovitis also seems to play a role in the progression of cartilage loss in knee OA 44 . Using arthroscopy to define synovial abnormalities, Ayral et al. 45 found that 29% of knees with OA had a reactive aspect (a proliferation of opaque villi), and 21% had an inflammatory aspect (hypervascularization of the synovial membrane and/or proliferation of hypertrophic and hyperaemic villi). Interestingly, an association with cartilage loss at 1-year follow-up was found only in the group with inflammatory synovitis 45 . The bone phenotype of knee OA would be characterized by large BMLs in one or several compartments (Fig. 1) . BMLs are defined on fluid-sensitive fat-suppressed MRI sequences as non-cystic subchondral a b 
Box 1 | Joint structural imaging to determine eligibility for OA clinical trials
Radiography is commonly used to assess joint structure when determining patient eligibility for clinical trials of potential disease-modifying osteoarthritis drugs (DmoADs). However, this imaging modality has a number of limitations. many of these limitations do not apply to mRI, and the feasibility of using mRI is increased by a number of technological advances.
Limitations of radiography
• Detailed characterization of the various structural phenotypes of osteoarthritis (oA) is not possible using radiography.
• Definition of structural disease severity using radiography is insufficient.
• Radiography is not able to depict exclusionary findings or is able to visualize these findings only at advanced stages.
• Patients undergoing radiography are exposed to ionizing radiation.
• Inclusion or exclusion of potential trial participants on the basis of radiographic findings could be one of the reasons for the failure of DmoAD clinical trials.
Advances of MRI-based assessment
• Fast image acquisition (5 min or less) is possible using modern mRI techniques, thus improving the feasibility of mRI and markedly reducing acquisition costs.
• mRI is not associated with any radiation concerns and has very few contraindications.
• Simplified image assessment tools could enable cost-efficient and timely evaluation of mRI data sets for assessment of eligibility for clinical trials.
• mRI enables patient stratification according to structural oA phenotypes, including inflammatory, bone, biomechanical (meniscus or cartilage), hypertrophic, atrophic and fast-progression phenotypes.
• mRI, but not radiography, permits early detection of factors that increase the risk of joint collapse (for example, subchondral insufficiency fracture, osteonecrosis, meniscal root tears, malignant bone marrow infiltration and synovial tumours); joints at high risk of collapse must be excluded from DmoAD trials. areas of ill-defined hyperintensity that are commonly seen together with cartilage damage in the same area 46, 47 . BMLs are important predictors of subsequent structural progression and symptom fluctuation in knee OA and have thus become a treatment target for novel therapeutic approaches 23, 48, 49 . A meniscal phenotype will exhibit meniscal damage and/or meniscal extrusion on MRI. Load distribution and shock absorption by the meniscus are crucial in protecting the tibiofemoral compartments. Meniscal morphology is rarely normal in knee compartments affected by OA; instead, the meniscus is often torn, shows substance defects or is even totally destroyed 50 .
Although an extensive radiological literature on the different types of meniscal pathology is available, little emphasis is placed on the relevance of these differences to incident OA or progression of disease 51 . MRI-determined meniscal pathology, including meniscal extrusion, is known to predict cartilage loss in the tibiofemoral compartments [52] [53] [54] (Fig. 5) .
A hypertrophic or atrophic OA phenotype can also be defined based on the presence or absence of osteophytes. A cross-sectional study that used a population-based cohort and evaluated different phenotypes of knee OA on MRI demonstrated that severe cartilage damage in the knee is commonly associated with large osteophytes 27 . However, osteophyte formation can lag behind cartilage loss, in which case OA might manifest as an atrophic OA phenotype characterized by an absence of osteophytes or only tiny osteophytes but with marked cartilage loss. With the use of a stringent MRI-based definition of atrophic knee OA, such a phenotype has a very low prevalence in the general population 27 . Currently, no radiography-based definition of atrophic OA exists, with this entity usually being identified by definite joint space narrowing without any osteophytes, or by a marked discordance between joint space narrowing and the size of associated osteophyte formation. A 2017 study in the Multicenter Osteoarthritis Study (MOST) cohort showed, surprisingly, that the progression of joint space narrowing and cartilage loss was less likely to be associated with the atrophic phenotype of knee OA (based on radiographic and MRI definitions) than non-atrophic knee OA 55 . In addition to these five distinct structural phenotypes, features visible on MRI, such as meniscal extrusion and prevalent meniscal structural damage, BMLs and prevalent cartilage lesions in knees at baseline -or combinations thereof -could be used to identify a subpopulation at high risk of progressive cartilage loss within a short time interval. Although measurable quantitative cartilage loss over a 6-month time period is thought to be rare, data from the Joints on Glucosamine Study suggest that cartilage loss, as well as the development or progression of BMLs and meniscal extrusion, does occur within this time frame 56 , suggesting that some of these MRI-detected structural changes could be used as outcomes. In addition, in the MOST cohort, the presence of a high BMI, meniscal damage, synovitis or effusion, or any severe MRI-detectable lesions at baseline were strongly associated with an increased risk of rapid cartilage loss over a 30-month period 57 , which suggests that assessment of such features could enable the selection of a trial population at high risk of disease progression. Although it is not known whether knees at increased risk of disease progression would be more likely to benefit from a pharmacological intervention than others, including such patients in clinical trials could increase the efficiency of the trials by decreasing their overall duration. Thus, these MRI-based risk factors could be used to select individuals for inclusion in trials of preventive or therapeutic interventions for OA, depending on the trial length.
Exclusionary findings. Some diagnoses should preclude eligibility for clinical DMOAD trials, and ideally should be identified during screening, as these conditions will not be amenable to treatment with a DMOAD and will show a negative outcome regardless of potential treatment of OA with a DMOAD [11] [12] [13] . These diagnoses include subchondral insufficiency fractures, meniscal root tears, malignant bone marrow infiltration or synovial tumours such as pigmented villonodular synovitis 14 , which are identifiable by MRI but are not covered by current assessment tools and are occult on radiography until very late in the course of the disease. Examples of diagnoses that should be exclusion criteria for DMOAD clinical trials are presented in Fig. 6 .
Subchondral insufficiency fractures of the knee are difficult to detect and can have an unpredictable course owing to delayed diagnosis and lack of standard treatment approaches. Prognoses can range from full recovery to rapidly escalating joint destruction 58 . Meniscal root tear is a subtype of radial tear that has gained increasing attention in the field of OA research. The ligamentous meniscal root enables essential meniscal functions including axial load distribution. Its rupture results in a compromise of the loading profile in the knee joint owing to meniscal extrusion and subsequent increased tibiofemoral contact pressures [59] [60] [61] [62] [63] [64] . Medial posterior root tears result in severe medial instability of the knee, clinically 65 , and a greater degree of ipsilateral femoral condyle degeneration than other types of meniscal tear 66 . The altered biomechanics resulting from root tears will probably override any potential DMOAD effect, although no evidence is available to date.
Tumours of the knee joint, both benign and malignant, although rare, might be observed as incidental findings in screening efforts. Although initial radiographs might be normal, MRI enables detailed assessment of bone and soft tissue involvement. Concomitant bone marrow oedema-like signal changes can be observed at almost all stages of various tumours 46, 67, 68 . Diffuse infiltration of the bone marrow might be observed in several haematological and oncological diseases, such as lymphoma, multiple myeloma and others. On MRI, this infiltration will be reflected as diffuse marrow alterations with signal characteristics that may appear similar but need to be differentiated from physiological periarticular red marrow, which appears as hyperintensity on fluid-sensitive fat suppressed sequences and as hypointensity on T1-weighted MRI sequences 46 . Other imaging modalities In this Opinion article, we focus on MRI as an alternative to radiography for use in screening efforts to assess eligibility for clinical trials in knee OA. We argue that the advantages of MRI outweigh the inherent limitations of the technique, including cost, examination time and availability, which can, at least in part, be overcome. Other imaging modalities have only been marginally discussed as they probably will not be able to represent an alternative to radiography for evaluating clinical trial eligibilitywith the exception of ultrasonography, which could be applied to screening of patients for signs of inflammation in trials focusing on anti-inflammatory therapeutic approaches or for determining the presence of osteophytes [69] [70] [71] . Nuclear medicine techniques, such as bone scintigraphy or PET, do not seem suitable for large-scale screening as they require the use of ionizing radiation and pose logistical challenges (for example, availability and transport of tracer) [72] [73] [74] . CT is an important and widely available imaging tool but shares some of the shortcomings of radiography in that it is a radiography-based technique and as such is characterized by low soft tissue contrast; however, CT is well suited to visualizing bony changes in OA 75 .
Conclusions
The shortcomings of radiography-based eligibility could have contributed, at least in part, to the failure of potential DMOADs in clinical trials to date. MRI can help investigators select study participants who are most suitable for the specific aim of a trial, taking into account disease phenotypes and the potential target or targets of the treatment being investigated. Technical advances that facilitate accelerated image acquisition and the development of simplified assessment tools could make the use of MRI feasible in screening patients for eligibility for such trials, including phenotypic characterization, identification of exclusionary findings (for reasons of safety and limiting potential adverse events) and identification of joints at high risk of rapid disease progression. Potential hurdles are costs and access to MRI systems, but these potential limitations can be overcome with ongoing methodological advances. The use of MRI in determining eligibility for DMOAD trials should result in better-targeted treatment and minimize one of the reasons for failure of DMOAD trialsthat is, not including the right patient for the right treatment. In summary, the time has come to no longer rely entirely on radiography to define eligibility for clinical trials in OA research. and marked surrounding bone marrow oedema (white arrows) that were not visible on the radiograph. g | The follow-up MRI, corresponding to the radiograph in part e, depicts increased deformity of the articular surface and diffuse concomitant bone marrow oedema at the medial femur and tibia (arrows). Additional marrow reconversion is evident on MRI, with red bone marrow extending into the distal metaphyseal femur and tibia (asterisk), a finding not to be confused with malignant bone marrow infiltration.
